Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe

Cellular Signalling

Volumn 25, Issue 5, 2013, Pages 1108-1117

  Cives, Mauro ^a   Ciavarella, Sabino ^a   Rizzo, Francesca Maria ^a   De Matteo, Monica ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Apoptosis; Bendamustine; Drug resistance; Melphalan; Mitotic catastrophe; Multiple myeloma

Indexed keywords

AURORA A KINASE; BENDAMUSTINE; CASPASE 2; CYCLIN B1; MELPHALAN; POLO LIKE KINASE 1;

ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL MICRONUCLEATION; CELL SURVIVAL; CELLULAR PARAMETERS; CHROMOSOMAL PARAMETERS; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ERRATIC CHROMOSOME SPREADING; G2 PHASE CELL CYCLE CHECKPOINT; M PHASE CELL CYCLE CHECKPOINT; MITOSIS INHIBITION; MITOSIS SPINDLE; MYELOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN B1; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MELPHALAN; MITOSIS; NITROGEN MUSTARD COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84874960074     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2013.01.020     Document Type: Article

References (50)

1. Palumbo A., Anderson K. The New England Journal of Medicine 2011, 364:1046-1060.
2. Sunters A., Springer C.J., Bagshawe K.D., Souhami R.L., Hartley J.A. Biochemical Pharmacology 1992, 44:59-64.
3. Dalton W.S. Seminars in Hematology 1997, 34:3-8.
4. Filipits M., Drach J., Pohl G., Schuster J., Stranzl T., Ackermann J., Königsberg R., Kaufmann H., Gisslinger H., Huber H., Ludwig H., Pirker R. Clinical Cancer Research 1999, 5:2426-2430.
5. Dalton W.S. Cancer Treatment Reviews 2003, 29:11-19.
6. Spanswick V.J., Craddock C., Sekhar M., Mahendra P., Shankaranarayana P., Hughes G., Hochhauser D., Hartley J.A. Blood 2002, 100:224-229.
7. Bellamy W.T., Dalton W.S., Gleason M.C., Grogan T.M., Trent J.M. Cancer Research 1991, 51:995-1002.
8. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernàndez-Luna J.L., Nuñez G., Dalton W.S., Jove R. Immunity 1999, 10:105-115.
9. Van de Donk N.W., Kamphuis M.M., van Dijk M., Borst H.P., Bloem A.C., Lokhorst H.M. Leukemia 2003, 17:211-219.
10. Tu Y., Renner S., Xu F., Fleishman A., Taylor J., Weisz J., Vescio R., Rettig M., Berenson J., Krajewski S., Reed J.C., Lichtenstein A. Cancer Research 1998, 58:256-262.
11. Wuilleme-Toumi S., Robillard N., Gomez P., Moreau P., Le Gouill S., Avet-Loiseau H., Harousseau J.L., Amiot M., Bataille R. Leukemia 2005, 19:1248-1252.
12. Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A.T. Blood 1993, 81:128-135.
13. Tucci M., Quatraro C., Dammacco F., Silvestris F. Current Topics in Medicinal Chemistry 2009, 9:218-224.
14. Strumberg D., Harstrick A., Doll K., Hoffmann B., Seeber S. Anti-Cancer Drugs 1996, 7:415-421.
15. Leoni L.M. Seminars in Hematology 2011, 48:S4-S11.
16. Leoni L.M., Bailey B., Reifert J., Bendall H.H., Zeller R.W., Corbeil J., Elliott G., Niemeyer C.C. Clinical Cancer Research 2008, 14:309-317.
17. von Minckwitz G., Chernozemsky I., Sirakova L., Chilingirov P., Souchon R., Marschner N., Kleeberg U., Tsekov C., Fritze D., Thomssen C., Stuart N., Vermorken J.B., Loibl S., Merkle K.H., Kaufmann M. Anti-Cancer Drugs 2005, 16:871-877.
18. Köster W., Stamatis G., Heider A., Avramidis K., Wilke H., Koch J.A., Stahl M. Clinical Drug Investigation 2004, 24:611-618.
19. Hartmann J.T., Mayer F., Schleicher J., Horger M., Huober J., Meisinger I., Pintoffl J., Käfer G., Kanz L., Grünwald V. Cancer 2007, 110:861-866.
20. Rummel M.J., Gregory S.A. Seminars in Hematology 2011, 48:S24-S36.
21. Michael M., Bruns I., Bölke E., Zohren F., Czibere A., Safaian N.N., Neumann F., Haas R., Kobbe G., Fenk R. European Journal of Medical Research 2010, 15:13-19.
22. Pönish W., Mitrou P.S., Merkle K., Herold M., Assmann M., Wilhelm G., Dachselt K., Richter P., Schirmer V., Schulze A., Subert R., Harksel B., Grobe N., Stelzer E., Schulze M., Bittrich A., Freund M., Pasold R., Friedrich T., Helbig W., Niederwieser D., Cancer Res J. Clinical Oncology 2006, 132:205-212.
23. Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. Haematologica 2005, 90:1287-1288.
24. Bröker L.E., Kruyt F.A.E., Giaccone G. Clinical Cancer Research 2005, 11:3155-3162.
25. Vitale I., Galluzzi L., Castedo M., Kroemer G. Nature Reviews. Molecular Cell Biology 2011, 12:385-392.
26. Ciavarella S., Grisendi G., Dominici M., Tucci M., Brunetti O., Dammacco F., Silvestris F. British Journal of Haematology 2012, 157:586-598.
27. De Matteo M., Brunetti A.E., Maiorano E., Cafforio P., Dammacco F., Silvestris F. Leukemia Research 2010, 34:243-249.
28. Drexler H.G., Matsuo Y. Leukemia 1999, 13:835-842.
29. UKCCCR British Journal of Cancer 2000, 82:1495-1509.
30. Cafforio P., Dammacco F., Gernone A., Silvestris F. Carcinogenesis 2005, 26:883-891.
31. Ciavarella S., Dammacco F., De Matteo M., Loverro G., Silvestris F. Stem Cells and Development 2009, 18:1211-1220.
32. Rödjer S., Swolin B., Weinfeld A., Westin J. Cancer Genetics and Cytogenetics 1990, 48:67-73.
33. Shi Y., Reiman T., Li W., Maxwell C.A., Sen S., Pilarski L., Daniel T.R., Penichet M.L., Feldman R., Lichtenstein A. Blood 2007, 109:3915-3921.
34. Portugal J., Mansilla S., Bataller M. Current Pharmaceutical Design 2010, 16:69-78.
35. Mansilla S., Bataller M., Portugal J. Anti-Cancer Agents in Medicinal Chemistry 2006, 6:589-602.
36. Gaul L., Weber S.M., Baumann P., Emmerich B., Schmidmaier R., Cancer Res J. Clinical Oncology 2008, 134:245-253.
37. Landau H.J., McNeely S.C., Nair J.S., Comenzo R.L., Asai T., Friedman H., Jhanwar S.C., Nimer S.D., Schwartz G.K. Molecular Cancer Therapeutics 2012, 11:1781-1788.
38. Damaj G., Malard F., Hulin C., Caillot D., Garidi R., Royer B., Marit G., Stoppa A.M., Banos A., Morineau N., Moreau P., Fitoussi O., Tiab M., Moreau P. Leukemia & Lymphoma 2012, 53:632-634.
39. Hazlehurst L.A., Enkemann S.A., Beam C.A., Argilagos R.F., Painter J., Shain K.H., Saporta S., Boulware D., Moscinski L., Alsina M., Dalton W.S. Cancer Research 2003, 63:7900-7906.
40. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., Dawson T.M., Dawson V.L., El-Deiry W.S., Fulda S., Gottlieb E., Green D.R., Hengartner M.O., Kepp O., Knight R.A., Kumar S., Lipton S.A., Lu X., Madeo F., Malorni W., Mehlen P., Nuñez G., Peter M.E., Piacentini M., Rubinsztein D.C., Shi Y., Simon H.U., Vandenabeele P., White E., Yuan J., Zhivotovsky B., Melino G., Kroemer G. Cell Death and Differentiation 2012, 19:107-120.
41. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Oncogene 2004, 23:2825-2837.
42. Wang X., Cheung H.W., Chun A.C., Jin D.Y., Wong Y.C. Frontiers in Bioscience 2008, 13:2103-2114.
43. Levesque A.A., Eastman A. Carcinogenesis 2007, 28:13-20.
44. Niida H., Tsuge S., Katsuno Y., Konishi A., Takeda N., Nakanishi M. The Journal of Biological Chemistry 2005, 280:39246-39252.
45. Stark G.R., Taylor W.R. Molecular Biotechnology 2006, 32:227-248.
46. Peters J.M. Nature Reviews. Molecular Cell Biology 2006, 7:644-656.
47. Wäsch R., Engelbert D. Oncogene 2005, 24:1-10.
48. Lens S.M.A., Voest E.E., Medema R.H. Nature Reviews. Cancer 2010, 10:825-841.
49. Castedo M., Perfettini J.L., Roumier T., Valent A., Raslova H., Yakushijin K., Horne D., Feunteun J., Lenoir G., Medema R., Vainchenker W., Kroemer G. Oncogene 2004, 23:4362-4370.
50. Fonseca R. Blood 2011, 118:6234-6235.